A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...

Serena Williams has a new doubles partner. The 23-time Grand Slam tennis champion is working with Ro, speaking out about how she used the direct-to-patient telehealth company to access GLP-1s for ...

(Reuters) -Telehealth company Ro has tapped tennis star Serena Williams as a celebrity patient ambassador for its weight-loss treatments, the company said Thursday. The 23-time Grand Slam champion, ...

New pill orforglipron was associated with a significant reduction in body weight and better cholesterol, triglycerides and blood pressure.

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite affordability, supply capacity, and growing demand in the U.S. market.

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...

(Reuters) -Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

(CNN) - Patients in the United States can now get the popular diabetes and weight loss drug Ozempic for half the price. Novo ...